Skip to main content

ResearchHubLoading navigation…

Loading ResearchHub…

Gynecologic Oncology | ResearchHub - ResearchHub

Explore the network

Research, people, journals and institutions — all in one place.

Explore

01Research 02Smart search 03Researchers 04Journals 05Institutions 06RHR Rankings 07ResearchHub platform 08Events

Work together

Turn ideas into projects, questions and reusable datasets.

Connect

01Projects 02Questions 03Datasets

Stay informed

Follow trends, opportunities and your research library.

Insights

01Research trends 02Opportunities 03Library 04Research services 05ResearchHub Pro 06Pricing

ResearchHub

Explore ResearchHub.

Personal

01Recommended research 02Research intelligence

Home Search Network Library Log in

ResearchHub

Research, connected

Explore the graph

ResearchGate

Download ResearchHub

GET IT ONGoogle PlayComing soonDownload on theApp StoreComing soonEXPLORE IT ONAppGalleryComing soon

Research

Research Researchers Journals Institutions RHR Rankings

Contribute

Projects Questions Datasets Opportunities

Platform

ResearchHub platform About Blog Community Help API Licensing

Shopping

Contact and support

Need help, have a question, or want to contact the ResearchHub team?

Contact and support support@aresearch.uk

© 2026 ResearchHub. Built for responsible scholarly connection.

Privacy Terms Cookies This work is licensed under Creative Commons Attribution 4.0 InternationalCC BY 4.0

Privacy-aware community infrastructure

Journal graph

Gynecologic Oncology

Elsevier BV · ISSN 0090-8258

3

Verified works

0

Citations

—

Access

Researchers publishing here

0 linked researchers

Linked researcher profiles will appear as verified work is indexed.

Research in this journal

Real-world clinical efficacy of pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide in heavily pretreated platinum-resistant ovarian cancer2026 · Gabriella Smith, Aaron Petty, Kevin Krivanek · 0 citations

Prevalence of pathogenic germline variants and indications for testing in a diverse community-based endometrial cancer cohort2026 · Elizabeth Suh-Burgmann, Yun-Yi Hung, Elizabeth Hoodfar · 0 citations

Farletuzumab ecteribulin, a folate receptor alpha (FRα) antibody-drug conjugate, in select advanced cancers: An open-label, multicenter, phase 1/2 dose-finding study2026 · Robert M. Wenham, Rebecca Kristeleit, Daniela Matei · 0 citations